Home › Companies › Whitehawk Therapeutics, Inc. › 2025-2026
At Whitehawk Therapeutics, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 52 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 163 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the named executive officers identified… — FOR was 79% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Whitehawk Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Whitehawk Therapeutics, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 11, 2026: 5 items on Whitehawk Therapeutics, Inc.’s Form 8-K, filed June 12, 2026: 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Whitehawk Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Whitehawk Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Behzad Aghazadeh, Ph.D. | 26,666,124 | -- | -- | 5,867,225 | 7,841,674 | 82% | Not verified | — |
| Elect Director: Richard Maroun | 27,701,332 | -- | -- | 4,832,017 | 7,841,674 | 85% | Not verified | — |
| Elect Director: Emma Reeve | 27,704,564 | -- | -- | 4,828,785 | 7,841,674 | 85% | Not verified | — |
| 2. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2025 Summary Compensation Table in the "Executive Compensation" section of the Proxy Statement | 22,896,061 | 6,013,600 | 3,623,688 | -- | 7,841,674 | 79% | Not verified | — |
| 3. Ratification of the appointment of BDO USA, P.C | 34,795,850 | 1,148,282 | 4,430,891 | -- | -- | 97% | Not verified | — |
Source: Whitehawk Therapeutics, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
Each item below shows how the 52 asset managers that disclosed a Whitehawk Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal: Behzad Aghazadeh, Ph.D.
Whitehawk Therapeutics, Inc.’s own tally for this item (“Elect Director: Behzad Aghazadeh, Ph.D.”): 26,666,124 for, 5,867,225 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,698,168 for, 227,397 withheld, 5,928 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,293,037 | 0 | 11 | 2,721 | For |
| Fidelity | 369,224 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 215,284 | Withhold |
| BlackRock | 28,916 | 0 | 0 | 0 | For |
| Equitable | 6,991 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 5,917 | 0 | Abstain |
| Nationwide | 0 | 0 | 0 | 5,296 | Withhold |
| American Century | 0 | 0 | 0 | 2,192 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 1,704 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 200 | Withhold |
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal: Emma Reeve
Whitehawk Therapeutics, Inc.’s own tally for this item (“Elect Director: Emma Reeve”): 27,704,564 for, 4,828,785 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,921,141 for, 4,425 withheld, 5,927 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,293,038 | 0 | 10 | 2,721 | For |
| Fidelity | 369,224 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 215,284 | 0 | 0 | 0 | For |
| BlackRock | 28,916 | 0 | 0 | 0 | For |
| Equitable | 6,991 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 5,917 | 0 | Abstain |
| Nationwide | 5,296 | 0 | 0 | 0 | For |
| American Century | 2,192 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 1,704 | Withhold |
| Blackstone Alternative Investment Funds | 200 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation, death or removal: Richard Maroun
Whitehawk Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard Maroun”): 27,701,332 for, 4,832,017 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,921,141 for, 4,425 withheld, 5,927 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,293,038 | 0 | 10 | 2,721 | For |
| Fidelity | 369,224 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 215,284 | 0 | 0 | 0 | For |
| BlackRock | 28,916 | 0 | 0 | 0 | For |
| Equitable | 6,991 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 5,917 | 0 | Abstain |
| Nationwide | 5,296 | 0 | 0 | 0 | For |
| American Century | 2,192 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 1,704 | Withhold |
| Blackstone Alternative Investment Funds | 200 | 0 | 0 | 0 | For |
Combines 8 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the named executive officers identified in the 2025 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.
Whitehawk Therapeutics, Inc.’s own tally for this item (“2. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2025 Summary Compensation Table in the "Executive Compensation" section of the Proxy Statement”): 22,896,061 for, 6,013,600 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,294,445 | 1,318 | 7 | 0 | For |
| Fidelity | 369,224 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 215,284 | 0 | 0 | Against |
| BlackRock | 28,916 | 0 | 0 | 0 | For |
| Equitable | 6,991 | 0 | 0 | 0 | For |
| Jackson National | 0 | 5,917 | 0 | 0 | Against |
| Nationwide | 0 | 5,296 | 0 | 0 | Against |
| American Century | 2,192 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 1,704 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 200 | 0 | 0 | 0 | For |
Fund voting reports, all 10 managers: 1,701,968 for, 229,519 against, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| QVT Financial LP | 0 | 0 | 4,596,289 | 0 | Abstain |
| ORBIMED ADVISORS LLC | 0 | 4,166,000 | 0 | 0 | Against |
| MONTANOVA CAPITAL, LLC | 3,700,000 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 3,471,752 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 2,082,000 | 0 | 0 | 0 | For |
| ACORN CAPITAL ADVISORS, LLC | 0 | 1,139,363 | 0 | 0 | Against |
| Ally Bridge Group (NY) LLC | 779,306 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 457,540 | 0 | 0 | 0 | For |
| Renaissance | 352,381 | 0 | 0 | 0 | For |
| Woodline Partners LP | 294,716 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 272,098 | 0 | 0 | Against |
| Eversept Partners, LP | 268,198 | 0 | 0 | 0 | For |
| Vanguard | 235,869 | 0 | 0 | 0 | For |
| BlackRock | 219,367 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 215,284 | 0 | 0 | Against |
| Two Sigma | 187,263 | 0 | 0 | 0 | For |
| State Street | 115,318 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 105,548 | 0 | 0 | 0 | For |
| Northern Trust | 69,255 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 65,194 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 55,562 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 28,000 | 0 | 0 | Against |
| Dimensional | 0 | 17,954 | 0 | 0 | Against |
| Point72 | 14,802 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 11,760 | 0 | 0 | Against |
Institutional-manager reports, all 42 managers: 12,493,640 for, 5,863,582 against, 4,596,289 abstained. Showing the 25 largest; every one is in the interactive database (link above).
97% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026.
Whitehawk Therapeutics, Inc.’s own tally for this item (“3. Ratification of the appointment of BDO USA, P.C”): 34,795,850 for, 1,148,282 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,931,483 for, 2 against, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,295,759 | 2 | 7 | 0 | For |
| Fidelity | 369,224 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 215,284 | 0 | 0 | 0 | For |
| BlackRock | 28,916 | 0 | 0 | 0 | For |
| Equitable | 6,991 | 0 | 0 | 0 | For |
| Jackson National | 5,917 | 0 | 0 | 0 | For |
| Nationwide | 5,296 | 0 | 0 | 0 | For |
| American Century | 2,192 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,704 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 200 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,452,463 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.62% |
| 2 | Fidelity | 0.75% |
| 3 | BRIDGEWAY FUNDS INC | 0.44% |
| 4 | BlackRock | 0.06% |
| 5 | Equitable | 0.01% |
| 6 | Jackson National | 0.01% |
| 7 | Nationwide | 0.01% |
| 8 | American Century | <0.01% |
| 9 | Lincoln Financial | <0.01% |
| 10 | Blackstone Alternative Investment Funds | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | QVT Financial LP | 9.29% |
| 2 | ORBIMED ADVISORS LLC | 8.42% |
| 3 | MONTANOVA CAPITAL, LLC | 7.48% |
| 4 | Avoro Capital Advisors LLC | 7.02% |
| 5 | Siren, L.L.C. | 4.21% |
| 6 | ACORN CAPITAL ADVISORS, LLC | 2.30% |
| 7 | Ally Bridge Group (NY) LLC | 1.58% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.93% |
| 9 | Renaissance | 0.71% |
| 10 | Woodline Partners LP | 0.60% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Behzad Aghazadeh | 36.99% | 13D |
| Fan Yu | 11.48% | 13G |
| ACUTA CAPITAL PARTNERS, LLC | 9.48% | 13D |
| OrbiMed Advisors LLC | 7.96% | 13G |
| Vanguard Group | 3.22% | 13F |
| Geode Capital | 0.93% | 13F |
| Renaissance Technologies | 0.87% | 13F |
| BlackRock | 0.71% | 13F |
| Millennium Management | 0.63% | 13F |
| Two Sigma | 0.55% | 13F |
Percentages above are of 49,452,463 shares outstanding, as reported by Whitehawk Therapeutics, Inc. on its Form 10-Q dated May 4, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Whitehawk Therapeutics, Inc.’s 10-Q dated May 4, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Whitehawk Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Whitehawk Therapeutics (WHWK) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/whitehawk-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.